Previous 10 | Next 10 |
Summary Danaher just reported its third-quarter earnings, which showed strong organic growth and pricing power despite economic challenges. The company is witnessing easing supply chain issues and confirmed its full-year outlook. Shares are down 25% year-to-date, which is a re...
Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The Dividend Champions list ...
Summary I discuss my top ten positions by industry, allowing me to focus on two or more companies I want to allocate to without worrying about weighting. My plan for my positions moving forward, whether I want them to be a larger or smaller portion of my portfolio. Some compan...
Danaher Corporation (DHR) Q3 2022 Results Conference Call October 20, 2022 08:00 AM ET Company Participants John Bedford - Vice President-Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Fina...
Danaher Corporation ( NYSE: DHR ) added ~3% pre-market Thursday after the life sciences company reported better than expected financials for Q3 2022 that its management attributed to the outperformance of all three segments. Washington, DC-based Danaher ( DHR ) o...
Danaher press release ( NYSE: DHR ): Q3 Non-GAAP EPS of $2.56 beats by $0.31 . Revenue of $7.66B (+5.9% Y/Y) beats by $490M . For the fourth quarter 2022, the Company anticipates that non-GAAP base business core revenue growth will be in the high-single digit p...
Danaher Reports Third Quarter 2022 Results PR Newswire WASHINGTON , Oct. 20, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter 2022. All results in this release reflect only continuing...
Life Sciences tool makers including Repligen ( NASDAQ: RGEN ) and Bio-Rad Laboratories ( NYSE: BIO ) are down in Wednesday trading after competitor Sartorius ( OTCPK:SARTF ) said it was seeing "a swift normalization of demand following two years influenced by stron...
Danaher ( NYSE: DHR ) is scheduled to announce Q3 earnings results on Thursday, October 20th, before market open. The consensus EPS Estimate is $2.25 (-5.9% Y/Y) and the consensus Revenue Estimate is $7.17B (-0.8% Y/Y). Over the last 2 years, DHR has beaten EPS estim...
Summary The management team at General Electric filed some valuable information regarding the upcoming spinoff of its healthcare operations. This new entity, GE HealthCare, is worth a significant amount of money, likely more than General Electric as a whole right now. This pre...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...